Journal Article
. 2021 Jun; 13:4233-4240.
doi: 10.2147/CMAR.S304820.

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study

Fuqun Wei 1 Qizhen Huang 2 Jian He 1 Liuping Luo 1 Yongyi Zeng 1 
  • PMID: 34079375
  •     21 References
  •     2 citations


Objective: Compared the outcomes between lenvatinib plus camrelizumab therapy and lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma (HCC) with progressive disease (PD).

Patients And Methods: A total of 48 advanced HCC patients were included in this retrospective study between June 2019 and March 2020. The patients were divided into the lenvatinib plus camrelizumab group (n=21) and the lenvatinib group (n=27). Primary endpoints were overall survival (OS) and progression-free survival (PFS), and secondary endpoints were the objective response rate (ORR) and adverse events (AEs).

Results: The median follow-up time was 8.4 months. The median OS was not obtained. The median PFS of lenvatinib plus camrelizumab group was significantly longer than that of lenvatinib group (8.0 months vs 4.0 months, p=0.011). Compared with lenvatinib group, lenvatinib plus camrelizumab group had higher ORR (28.57% vs 7.41%) and disease control rate (DCR) (71.43% vs 51.85%). The most common adverse events (AEs) included hand-foot skin reaction, hypertensions and abnormal hepatic function damage. Overall, 23.81% and 25.93% of patients experienced grade ≥3AEs in the lenvatinib plus camrelizumab group and the lenvatinib group, respectively.

Conclusion: Lenvatinib plus camrelizumab as post-progression treatment is effective and safe for advanced hepatocellular carcinoma with PD.

Keywords: PD-1; advanced hepatocellular carcinoma; lenvatinib.

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
Yu Kato, Kimiyo Tabata, +13 authors, Yasuhiro Funahashi.
PLoS One, 2019 Feb 28; 14(2). PMID: 30811474    Free PMC article.
Highly Cited.
New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.
Riccardo Lencioni.
Clin Cancer Res, 2013 Feb 06; 19(6). PMID: 23382112
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Shukui Qin, Zhenggang Ren, +13 authors, Jianjun Zou.
Lancet Oncol, 2020 Mar 01; 21(4). PMID: 32112738
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Feng Wang, Shukui Qin, +15 authors, Jianjun Zou.
J Hematol Oncol, 2020 May 13; 13(1). PMID: 32393323    Free PMC article.
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Takayuki Kimura, Yu Kato, +10 authors, Kenichi Nomoto.
Cancer Sci, 2018 Nov 18; 109(12). PMID: 30447042    Free PMC article.
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.
Joong-Won Park, Minshan Chen, +8 authors, Morris Sherman.
Liver Int, 2015 Mar 11; 35(9). PMID: 25752327    Free PMC article.
Highly Cited.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, +17 authors, Josep M Llovet.
J Clin Oncol, 2020 Jul 28; 38(26). PMID: 32716739    Free PMC article.
Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kenichiro Kodama, Tomokazu Kawaoka, +10 authors, Hiroshi Aikata.
Oncology, 2019 Jun 27; 97(2). PMID: 31242488
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Xiaobo Yang, Junping Shi, +2 authors, Haitao Zhao.
Oncologist, 2020 Feb 27; 25(6). PMID: 32100934    Free PMC article.
Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.
Takeshi Hatanaka, Satoru Kakizaki, +10 authors, Toshio Uraoka.
Hepatol Res, 2019 Nov 25; 50(3). PMID: 31760660
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens.
Cancers (Basel), 2019 Oct 17; 11(10). PMID: 31615069    Free PMC article.
Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Takamasa Ohki, Koki Sato, +8 authors, Shuntaro Obi.
Drugs Real World Outcomes, 2020 Feb 13; 7(2). PMID: 32048238    Free PMC article.
Hepatocellular carcinoma.
Alejandro Forner, María Reig, Jordi Bruix.
Lancet, 2018 Jan 09; 391(10127). PMID: 29307467
Highly Cited. Review.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, +18 authors, KEYNOTE-240 investigators.
J Clin Oncol, 2019 Dec 04; 38(3). PMID: 31790344
Highly Cited.
Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).
Jinlin Hou, Guiqiang Wang, +18 authors, Chinese Society of Infectious Diseases, Chinese Medical Association.
J Clin Transl Hepatol, 2017 Dec 12; 5(4). PMID: 29226097    Free PMC article.
Highly Cited.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, +19 authors, Ann-Lii Cheng.
Lancet, 2018 Feb 13; 391(10126). PMID: 29433850
Highly Cited.
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
Takeshi Terashima, Tatsuya Yamashita, +11 authors, Shuichi Kaneko.
Hepatol Res, 2020 Apr 21; 50(7). PMID: 32307874
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, +3 authors, Lewis R Roberts.
Nat Rev Gastroenterol Hepatol, 2019 Aug 24; 16(10). PMID: 31439937    Free PMC article.
Highly Cited. Review.
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Jianming Xu, Yun Zhang, +12 authors, Quanren Wang.
Clin Cancer Res, 2018 Oct 24; 25(2). PMID: 30348638
Highly Cited.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, +19 authors, IMbrave150 Investigators.
N Engl J Med, 2020 May 14; 382(20). PMID: 32402160
Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy.
Qing-Yu Xie, Hai-Yan Liu, +5 authors, Shun-Jun Fu.
Front Mol Biosci, 2022 Feb 22; 8. PMID: 35187075    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.